Comparison of Non-Vitamin K Antagonist Oral Anticoagulants on Ischemic Stroke and Bleeding

Main Article Content

Betül Özenç
Oğuzhan Kurşun

Abstract

Objective: Non-vitamin K antagonist oral anticoagulants (NOACs) have become widely utilized for various clinical indications, including non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), and apical thrombus. Despite their increasing popularity, limited comparative data exist on the clinical outcomes associated with different NOACs. This study aims to address this gap by directly comparing NOACs in terms of ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding.


Materials and Methods: A retrospective search of the electronic database was conducted to identify patients using NOACs for NVAF, DVT, and apical thrombus. Clinical outcomes, including ischemic stroke, hemorrhagic stroke, and gastrointestinal bleeding, were directly compared among different NOACs. The chi-square test and Fisher's exact test were employed to assess the relative incidence of stroke and extracranial complications across four patient groups.


Results: Among the 4,112 retrospectively analyzed patients, 55 were included in the study. Demographic and clinical profiles showed no significant differences among patients in the four different drug groups (p > 0.05). Ischemic stroke was observed in 90.9% of the patients, hemorrhagic stroke in 5.8%, and gastrointestinal bleeding in 3.3%. A statistically significant difference was identified between drug doses and the rate of ischemic stroke (p < 0.001).


Conclusion: The findings of this retrospective study carry significant implications, especially considering the widespread global use of NOACs. The study revealed no discernible difference in the risk of ischemic stroke among patients using different NOACs. Notably, the risk of hemorrhagic stroke was dose-dependent in the dabigatran group, while rivaroxaban was associated with the highest risk of gastrointestinal bleeding. Given the elevated rate of thromboembolism in patients and the relatively short half-life of NOACs, the study concludes that further optimization of NOAC use is imperative.

Downloads

Download data is not yet available.

Article Details

How to Cite
Özenç, B., & Kurşun, O. (2023). Comparison of Non-Vitamin K Antagonist Oral Anticoagulants on Ischemic Stroke and Bleeding. Medical Science and Discovery, 10(12), 975–979. https://doi.org/10.36472/msd.v10i12.1097
Section
Research Article
Received 2023-11-05
Accepted 2023-11-23
Published 2023-12-06

References

Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996 Oct;27(10):1765-9. doi: 10.1161/01.str.27.10.1765. PMID: 8841326.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et.al ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PMID: 24251359.

Stojanovski BM, Di Cera E. Comparative sequence analysis of vitamin K-dependent coagulation factors. J Thromb Haemost. 2022 Dec;20(12):2837-2849. doi: 10.1111/jth.15897. Epub 2022 Oct 11. PMID: 36156849; PMCID: PMC9669250.

Bortman LV, Mitchell F, Naveiro S, Pérez Morales J, Gonzalez CD, Di Girolamo G et.al. Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation. J Clin Pharmacol. 2023 Apr;63(4):383-396. doi: 10.1002/jcph.2184. Epub 2023 Jan 29. PMID: 36433678.

Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011; 31:326–343. doi: 10.1007/s11239-011-0561-1.

Şimşek UB, Özdağ MF. The Relationship of Carotid Artery Plaque and Stenosis with Microemboli. Medical Science and Discovery 10.10 (2023): 894-900.

Choi SE, Sagris D, Hill A, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther. 2023 Jan;21(1):35-56. doi: 10.1080/14779072.2023.2160319. Epub 2023 Jan 8. PMID: 36537565.

Brodie MM, Newman JC, Smith TS, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. American Journal of Medicine 2017; 9343(17):31198-1.

Vespa PM. Oral anticoagulants and the risk of intracranial hemorrhage. JAMA. 2014; 312:2562–2563. doi: 10.1001/jama.2014.12180.

Shpak M, Ramakrishnan A, Nadasdy Z, Cowperthwaite M, Fanale C. Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. Stroke. 2018 Dec;49(12):2851-2856. doi: 10.1161/STROKEAHA.118.022636. PMID: 30571404.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.

Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S et.al. ELDERCARE-AF Committees and Investigators. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 29;383(18):1735-1745. doi: 10.1056/NEJMoa2012883. Epub 2020 Aug 30. PMID: 32865374.

How CH. Novel oral anticoagulants for atrial fibrillation. Singapore Med J.2015; 56:657–658; quiz 659. doi: 10.11622/smedj.2015.